Table 2.

Fatty acid derivatives in tumor tissue

Eicosanoid (ng/mg protein)Control dietControl + EPA+DHADIODIO + EPA+DHA
for M-Wntn = 9n = 5n = 9n = 9
for Wnt-1n = 9n = 5n = 8n = 9
M-Wnt 6ketoPGF1α12.2 ± 4.73.9 ± 1.7a12.7 ± 3.3b22.9 ± 8.9b
Wnt-1 6ketoPGF1α3.5 ± 1.33.2 ± 1.89.4 ± 6.14.2 ± 2.3
M-Wnt TXB244.6 ± 12.713.5 ± 5.3128.2 ± 45.280.4 ± 23.1
Wnt-1 TXB23.9 ± 1.41.2 ± 0.47.9 ± 4.83.2 ± 1.4
M-Wnt PGF2α3.3 ± 0.9a1.1 ± 0.7a8.8 ± 3.37.6 ± 1.8b
Wnt-1 PGF2α1.9 ± 0.80.23 ± 0.063.1 ± 1.91.7 ± 0.8
M-Wnt PGE29.0 ± 2.84.4 ± 1.0a10.0 ± 2.813.6 ± 1.6b
Wnt-1 PGE28.6 ± 3.72.3 ± 0.918.3 ± 9.45.4 ± 2.3
M-Wnt PGE30.11 ± 0.040.085 ± 0.037a0.071 ± 0.017a0.25 ± 0.08b
Wnt-1 PGE30.08 ± 0.030.03 ± 0.010.14 ± 0.070.15 ± 0.09
M-Wnt PGD2144.2 ± 51.199.8 ± 42.4a385.1 ± 62.4b220.6 ± 67.3
Wnt-1 PGD25.7 ± 2.31.4 ± 0.68.9 ± 4.44.3 ± 1.6
M-Wnt 13HODE40.3 ± 10.312.4 ± 6.7a47.9 ± 17.699.0 ± 30.2b
Wnt-1 13HODE2.6 ± 1.1a2.1 ± 1.7a12.8 ± 5.311.0 ± 2.6b
M-Wnt 15HETE9.5 ± 2.83.2 ± 0.8a28.4 ± 9.5b17.5 ± 4.9b
Wnt-1 15HETE1.3± 0.50.61 ± 0.17a4.1 ± 1.9b2.1 ± 0.6
M-Wnt 12HETE28.6 ± 9.812.2 ± 3.8a31.5 ± 9.832.9 ± 8.1b
Wnt-1 12HETE21.9 ± 6.85.6 ± 1.5a39.3 ± 17.620.1 ± 4.8b
M-Wnt 5HETE3.2 ± 0.7a2.1 ± 0.5a28.9 ± 11.9b8.9 ± 2.6b
Wnt-1 5HETE0.65 ± 0.150.60 ± 0.191.6 ± 0.50.87 ± 0.19
M-Wnt 18HEPE0.004 ± 0.004a0.038 ± 0.016b0.037 ± 0.012b0.053 ± 0.030
Wnt-1 18HEPENANANANA

NOTE: 6-ketoPGF1α, 6-keto prostaglandin F1α; TXB2, thromboxane B2; PGE3, prostaglandin E3; PGF2α, prostaglandin F2α; PGE2, prostaglandin E2; PGD2, prostaglandin D2; 13HODE, 13-hydroxyoctadecadienoic acid; 15HETE, 15-hydroxyeicosatetraenoic acid; 12HETE, 12-hydroxyeicosatetraenoic acid; 5HETE, 5-hydroxyeicosatetraenoic acid; 18HEPE, 18-HEPE acid. Statistically significant (P ≤ 0.05) differences are indicated by different letters, e.g., a group designated with a is different than a group designated with b; but two groups with a are not different.